Horne C, Spahn H, Mutschler E, Knauf H
Pharmakologisches Institut für Naturwissenschaftler der Johann Wolfgang Goethe-Universität, Frankfurt/Main, Fed. Rep. of Germany.
Arzneimittelforschung. 1987 Aug;37(8):956-9.
A method for the simultaneous determination of the cardiovascular agent verapamil and its major metabolite norverapamil in human plasma is described. Analysis is performed after alkaline extraction with n-heptane by subsequent ion-paired high performance liquid chromatographic (HPLC) separation, and direct fluorimetric measurement of both compounds (lambda maxex. = 278 nm, lambda maxem. = 320 nm). The sensitivity of the procedure (detection limit less than 1 ng/ml) is suitable for pharmacokinetic studies after therapeutic doses. The applicability of the method was tested by performing a clinical study. Plasma concentrations of two verapamil formulations for oral administration were examined. The active metabolite norverapamil was included in the investigation.
本文描述了一种同时测定人血浆中心血管药物维拉帕米及其主要代谢产物去甲维拉帕米的方法。采用正庚烷碱性萃取后，通过离子对高效液相色谱（HPLC）分离，然后对两种化合物进行直接荧光测定（激发波长λmaxex. = 278 nm，发射波长λmaxem. = 320 nm）。该方法的灵敏度（检测限小于1 ng/ml）适用于治疗剂量后的药代动力学研究。通过进行一项临床研究来测试该方法的适用性。检测了两种口服维拉帕米制剂的血浆浓度。活性代谢产物去甲维拉帕米也包含在研究中。
